このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Cantargia 過去の業績

過去基準チェック /06

Cantargiaの収益は年平均-22%で減少しているが、Biotechs業界はgrowingで11.8%年平均の収益となった。

主要情報

-22.0%

収益成長率

-7.3%

EPS成長率

Biotechs 業界の成長	0.7%
収益成長率	n/a
株主資本利益率	-181.3%
ネット・マージン	n/a
次回の業績アップデート	28 Aug 2024

Recent updates

An Intrinsic Calculation For Cantargia AB (publ) (STO:CANTA) Suggests It's 47% Undervalued

May 31

Here's Why We're Not Too Worried About Cantargia's (STO:CANTA) Cash Burn Situation

May 02

Is Cantargia (STO:CANTA) In A Good Position To Invest In Growth?

Jan 10

We Think Cantargia (STO:CANTA) Can Easily Afford To Drive Business Growth

Sep 20

収支内訳

Cantargia の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

OM:CANTA 収益、費用、利益 ( )SEK Millions
日付	収益	G+A経費	研究開発費
31 Mar 24	-241	14	238
31 Dec 23	-280	15	273
30 Sep 23	-299	14	293
30 Jun 23	-293	15	287
31 Mar 23	-330	15	321
31 Dec 22	-372	15	365
30 Sep 22	-385	15	379
30 Jun 22	-419	15	410
31 Mar 22	-411	16	400
31 Dec 21	-367	15	353
30 Sep 21	-319	16	304
30 Jun 21	-255	16	239
31 Mar 21	-206	15	191
31 Dec 20	-173	15	158
30 Sep 20	-153	15	138
30 Jun 20	-139	14	126
31 Mar 20	-127	14	113
31 Dec 19	-111	13	97
30 Sep 19	-102	12	90
30 Jun 19	-98	14	83
31 Mar 19	-101	16	85
31 Dec 18	-91	16	77
30 Sep 18	-78	10	104
30 Jun 18	-68	9	87
31 Mar 18	-56	7	65
31 Dec 17	-60	7	52
30 Sep 17	-65	14	0
30 Jun 17	-66	13	0
31 Mar 17	-58	12	0
31 Dec 16	-47	12	0
30 Sep 16	-34	12	0
30 Jun 16	-24	11	0
31 Mar 16	-22	11	0
31 Dec 15	-17	10	0
30 Sep 15	-15	8	0
30 Jun 15	-14	7	0
31 Mar 15	-10	6	0
31 Dec 14	-8	5	0

質の高い収益: CANTAは現在利益が出ていません。

利益率の向上: CANTAは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: CANTAは利益が出ておらず、過去 5 年間で損失は年間22%の割合で増加しています。

成長の加速: CANTAの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: CANTAは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 3% ) と比較することは困難です。

株主資本利益率

高いROE: CANTAは現在利益が出ていないため、自己資本利益率 ( -181.3% ) はマイナスです。

Cantargia 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Cantargia AB (publ) to Report Fiscal Year 2024 Results on Feb 21, 2025

Cantargia AB (publ) to Report Q2, 2024 Results on Aug 28, 2024

Cantargia AB (publ) to Report Q1, 2024 Results on May 21, 2024

Cantargia AB (publ) to Report Q2, 2023 Results on Aug 22, 2023

Recent updates

Cantargia AB (Publ) Reports Further Progress in Ongoing Phase 1 Clinical Trial with CAN10

Cantargia AB (Publ) Announces Appointment of Ton Berkien as Chief Business Officer, Effective October 1, 2024

Insufficient new directors

Cantargia Presents New Positive Clinical Data on Nadunolimab Counteracting Chemotherapy Induced Neuropathy

Forecast to breakeven in 2026

New major risk - Revenue and earnings growth

We're A Little Worried About Cantargia's (STO:CANTA) Cash Burn Rate

Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition

Cantargia AB (publ) Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal

New minor risk - Share price stability

Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis

Cantargia AB (publ) Reports Progress Towards Start of DOT-Sponsored Clinical Trial of Nadunolimab in Leukemia

Cantargia Reports New Data Highlighting Potential of CAN10 Antibody, Currently in Phase I Clinical Development, as Therapy in Systemic Sclerosis

Cantargia Reports New Preclinical Data on Antitumor Effects of nadunolimab in Pancreatic Cancer

Price target decreased by 7.3% to kr12.67

Forecast to breakeven in 2026

New major risk - Financial position

Cantargia AB (publ) to Report Fiscal Year 2024 Results on Feb 21, 2025

Cantargia Reports US Regulatory Approval to Start Pancreatic Cancer Phase IIB Trial with Nadunolimab

Cantargia Reports New Data Reinforcing Nadunolimab as Cancer Combination Therapy

Chief Executive Officer recently bought kr104k worth of stock

Cantargia Reports Phase I Clinical Progress in the CAN10 Project

Cantargia Reports New Preclinical Data Confirming the Potential of Nadunolimab and Can10

Chief Executive Officer recently bought kr103k worth of stock

New major risk - Revenue and earnings growth

New major risk - Financial position

Cantargia AB (publ) to Report Q2, 2024 Results on Aug 28, 2024

Cantargia AB (publ), Annual General Meeting, May 23, 2024

New minor risk - Shareholder dilution

Cantargia Presents New Clinical Data Further Supporting Nadunolimab's Antitumor Activity and A Key Role of Its Target IL1RAP in Pancreatic Cancer

Cantargia Reports New Preclinical Data on nadunolimab Potential to Enhance Anti-Tumor Effect of Immunotherapy Presented at CRI-ENCI-AACR

Cantargia AB (publ) Announces New Nadunolimab Clinical Trial in Leukemia Financed by External US Grant

Cantargia AB (publ)Expands Clinical Pipeline and Starts Treatment in Second Program, CAN10, for Autoimmune Diseases

No longer forecast to breakeven

New major risk - Financial position

Cantargia AB (publ) to Report Q1, 2024 Results on May 21, 2024

Cantargia AB (publ) Receives Regulatory Approval to Start Phase I Clinical Trial for CAN10

New minor risk - Share price stability

Is Cantargia (STO:CANTA) In A Good Position To Deliver On Growth Plans?

Cantargia Publishes ASCO 2023 Poster on Promising Nadunolimab Efficacy in Non-Small Cell Lung Cancer

Cantargia AB (publ) Promotes David Liberg to Chief Scientific Officer

Cantargia Extends Development of Nadunolimab in Pancreatic Cancer with New Controlled Phase IIb Clinical Trial Following Strong Phase IIb Efficacy Results

We Think Cantargia (STO:CANTA) Can Afford To Drive Business Growth

Cantargia Appoints Patrik Renblad as Chief Financial Officer

Chief Executive Officer recently bought kr140k worth of stock

Cantargia AB (publ) Successfully Concludes Toxicity Study with Can10 Antibody Ahead of Phase I Clinical Trial Application

Cantargia AB (Publ) Announces Nomination Committee Appointments

Is Cantargia (STO:CANTA) In A Good Position To Invest In Growth?

Price target decreased to kr22.00

Cantargia's CAN10 Demonstrates Positive Activity in Systemic Sclerosis Models in New Data Presented At ACR Convergence 2022

Cantargia AB (Publ) Presents New Data At SITC 2022 Supporting Nadunolimab's Promising Antitumor Clinical Efficacy

Cantargia Reaches Recruitment Milestone and Focuses Nadunolimab Development on Upcoming Randomized Studies

Cantargia AB (publ) to Report Q2, 2023 Results on Aug 22, 2023

Cantargia Reports First Non-Squamous NSCLC Patient Treated with Nadunolimab, Keytruda® and Chemotherapy

Cantargia Reports Preclinical Data Demonstrating Unique Treatment Effects of nadunolimab on Pancreatic Cancer Stromal Cells

Cantargia AB (Publ) Publishes Preclinical Data on Strong Anti-Tumor Efficacy of Nadunolimab in Combination with Chemotherapy

Cantargia Reports New Positive Preclinical Efficacy Data for CAN10 Supporting Development in Myocarditis

Cantargia Receives USPTO Notice of Allowance for Composition of Matter Patent on Antibody CAN10

Cantargia AB (Publ) Announces Executive Changes

An Intrinsic Calculation For Cantargia AB (publ) (STO:CANTA) Suggests It's 47% Undervalued

Cantargia Announces ASCO 2022 Presentation Strengthens Positive Phase IIa interim results for nadunolimab in NSCLC

Cantargia AB (publ) Presents Clinical Interim Results At ASCO 2022 Highlighting the Potential of Nadunolimab in Combination with Checkpoint Inhibitor

Cantargia AB (publ) Reports Positive Preclinical Effects in Atherosclerosis Demonstrating Potential of Can10 in Cardiovascular Disease

Forecast breakeven date pushed back to 2024

Here's Why We're Not Too Worried About Cantargia's (STO:CANTA) Cash Burn Situation

Price target decreased to kr42.00

Forecast breakeven date pushed back to 2024

Insider recently bought kr88k worth of stock

Cantargia Reports Positive Preclinical Efficacy Data for CAN10 Demonstrating Anti-Fibrotic and Anti-Inflammatory Effects in Systemic Sclerosis

Cantargia AB (Publ) Reports Encouraging New CAN10 Toxicology Results and Schedules Phase I Trial for 2023

Cantargia AB Reports Treatment of First Non-Squamous Non-Small Cell Lung Cancer Patient in New Arm of CANFOUR Study

過去基準チェック /06